Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,414 total articles
Acumen Pharmaceuticals reported its Q1 2026 financial results and business highlights, emphasizing ongoing progress in its Phase 2 ALTITUDE-AD study for sabirnetug (ACU193), a novel Alzheimer's treatment targeting toxic amyloid beta oligomers. The company expects topline results by late 2026 and plans for an IND filing mid-2027 for its enhanced bra…
C4 Therapeutics reported progress in developing cemsidomide as a foundational multiple myeloma treatment, initiated multiple clinical trials, and expanded its partnership with Roche to develop degrader-antibody conjugates. The company maintains a strong cash position with a runway to the end of 2028, despite a net loss in Q1 2026. Upcoming trial da…
eToro Group Ltd. announced its first quarter 2026 results showing solid financial growth with net contribution rising 19% year-over-year to $258 million and net income up 37% to $82 million. The company expanded product offerings including 24/7 trading for commodities and equities, AI-powered tools, and launched crypto trading in New York. The acqu…
Cal-Maine Foods, Inc., the largest U.S. egg producer, announced the acquisition of the Van's Foods brand from Sara Lee Frozen Bakery. This strategic purchase aims to diversify Cal-Maine's portfolio by entering the better-for-you frozen breakfast segment, expanding prepared foods sales by an estimated 10% annually, and enhancing distribution across …
Colliers International’s U.S. Engineering division is partnering with Oklahoma City-based engineering firm Frankfurt-Short-Bruza Associates (FSB) to establish a national aviation practice and enhance capabilities in federal, mission-critical, and Native American sectors. The partnership will allow Colliers Engineering to access the high-barrier avi…
Olema Pharmaceuticals reported Q1 2026 financials and operational progress, emphasizing upcoming Phase 3 trial results for palazestrant (OPERA-01) expected in fall 2026 and ongoing enrollment in OPERA-02. The company also highlighted initial clinical data for OP-3136 to be presented at ASCO. With over $505 million in cash and expanding clinical pro…
Lantronix Inc. has introduced the xPico 600 series, a production-ready embedded gateway module featuring dual-band Wi-Fi 6, Bluetooth Low Energy 5.4, enterprise-grade security, and integration with their Percepxion cloud platform for zero-touch provisioning and remote device management. Designed to accelerate IoT product development and simplify de…
Seres Therapeutics, a clinical-stage biotechnology company focused on live biotherapeutics, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference, where it will present a company overview. The company is advancing several therapies, including SER-155 and SER-603, targeting inflammatory and immune diseases.
American Shared Hospital Services (AMS), a U.S.-based provider of advanced cancer treatment equipment and services through leasing and patient care segments, announced its first quarter 2026 financial results will be released ahead of a May 14th conference call. The company outlined plans to discuss growth and expansion in Gamma Knife, proton thera…
Applied Optoelectronics Inc. (AAOI) announced a partnership with Mediacom to enhance and expand Mediacom's fiber and coax network infrastructure through the deployment of DOCSIS 4.0 technology. AOI will supply key smart amplifiers and related products to increase network capacity, signal quality, and overall reliability. Mediacom aims to upgrade it…
Opus Genetics announced its financial results for Q1 2026 and provided updates on its gene therapy pipeline targeting inherited retinal diseases (IRDs). The company highlighted ongoing clinical trials, expected data readouts for its OPGx-BEST1 program, FDA acceptance of the LCA5 program into the Rare Disease Evidence Principles program, and plans t…
Tilray Brands' craft brewing division Blue Point Brewing has launched a new year-round IPA called Magic Hour IPA, featuring bright, tropical hop flavors with a 6% ABV. The brew is designed to capture the essence of golden hour relaxation and broaden Blue Point's offering to appeal to both IPA enthusiasts and casual beer drinkers. Magic Hour IPA is …
Broadwind's Q1 2026 results show a slight net loss but strong revenue growth and order increases in gearing and industrial solutions segments. The company announced the sale of its Abilene facility and exiting the wind tower production to focus on higher-growth, more profitable core businesses, improving quality of earnings and liquidity through a …
NovaBridge Biosciences announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company will discuss its innovative biotechnology platform and progress on key pipeline assets including givastomig and VIS-101, which address cancer and retinal vascular diseases respectively. The presentation fo…
Sionna Therapeutics announced the completion of enrollment in its Phase 2a trial evaluating SION-719 for cystic fibrosis, with topline data expected in summer 2026. Additionally, a Phase 1 trial testing combinations involving SION-451 is progressing on schedule. The company maintains a strong cash position of $289.9 million expected to fund operati…
Achieve Life Sciences announced its Q1 2026 financial results, successfully closing a $354 million private placement to fund its Phase 3 trial and commercialization of cytisinicline, a potential first new FDA-approved therapy for smoking and vaping cessation in over 20 years. The company appointed Andrew D. Goldberg, MD as CEO, expanded its board, …
Creative Realities, Inc., a NASDAQ-listed digital signage and AdTech solutions provider, announced its first quarter 2026 earnings release scheduled before market open on May 15, 2026, followed by a conference call. The company's offerings include digital signage-based experiences and programmatic advertising platforms across various sectors such a…
ProQR Therapeutics announced its Q1 2026 operating and financial results, highlighting advancement of its RNA editing pipeline including AX-0810 entering Phase 2 indication for biliary atresia, and upcoming clinical milestone data targeted in 2026 and 2027. The company also expanded its pipeline with AX-0811, AX-0422, and AX-2911 progressing toward…
AC Immune SA announced that its co-founder and CEO Dr Andrea Pfeifer will retire at the upcoming AGM after 23 years leading the company. Board Chair Dr Martin Zügel will serve as interim CEO during the search for a permanent successor. Dr Pfeifer will continue as an advisor and honorary board chair. The company remains well positioned with a robust…
Immatics N.V. announced its first quarter 2026 financial results and business updates, highlighting pivotal progress in its PRAME franchise, including the anticipated interim and final analyses from the pivotal Phase 3 SUPRAME trial of anzu-cel for advanced melanoma, expected in 2026, leading to a planned commercial launch in 2027. The company also…
Bitdeer Technologies Group (NASDAQ: BTDR) announced significant operational progress in April 2026, with Bitcoin production up 372% year-over-year to 783 BTC and self-mining hash rate exceeding 65.5 EH/s. The AI cloud segment showed robust month-over-month growth in annual recurring revenue (ARR), rising 60% to approximately $69 million. Notably, B…
Foghorn Therapeutics, a clinical-stage biotech firm focused on novel gene expression therapies for oncology, will participate in three prominent investor conferences in May 2026. Leadership will present the company's innovative Gene Traffic Control platform and pipeline at events including H.C. Wainwright Bioconnect, Stifel Virtual Targeted Oncolog…
Ovid Therapeutics reported solid progress in Q1 2026 including initiation of Phase 1 dosing for OV4071, expansion of OV329 into pediatric epilepsy indications, and a strengthened financial position following successful PIPE financing and warrant exercises. The company plans multiple Phase 2 studies targeting treatment-resistant epilepsies and pedia…
Tenax Therapeutics reported Q1 2026 financial results highlighting progress in its Phase 3 clinical trials for TNX-103, a novel therapy targeting pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company completed patient randomization in the LEVEL trial and expects topline data in Q3 2026. Additi…
Arvinas, Inc. and Pfizer entered into an agreement with Rigel Pharmaceuticals granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA-approved PROTAC drug for certain advanced breast cancers. Arvinas and Pfizer will receive $85 million upfront combined with potential milestones totali…
